|
专题报告 6月3日 1:00 PM - 2:15 PM 地点：S100a 扩展教育专场：脑转移的多学科管理 Use of Stereotactic Radiosurgery in Treating Brain Metastases: Is There a Role for Whole-Brain Radiation Therapy? 立体定向放射外科治疗脑转移：全脑放射治疗还有应用空间吗？ Paul D. Brown, MD The University of Texas MD Anderson Cancer Center Imaging and Clinical Endpoints in Brain Metastases Trials 脑转移试验中的影像学和临床研究终点 Riccardo Soffietti, MD University and San Giovanni Battista Hospital Targeted Therapy in Brain Metastases: Ready for Prime Time? 脑转移靶向治疗的黄金时代是否来临? Manmeet Singh Ahluwalia, MD - Chair Cleveland Clinic 6月4日4:45 PM - 6:00 PM 地点：Hall D2 Gianni Bonadonna奖颁奖仪式及获奖演说 雌激素受体和生长因子受体间的交联：内分泌治疗耐药的启示和新的对抗策略 Crosstalk Between Estrogen and Growth Factor Receptor Pathways: Implications for Endocrine Therapy Resistance and New Strategies to Overcome It C. Kent Osborne, MD Baylor College of Medicine 6月6日8:00 AM - 9:15 AM 地点：S100a 教育专场-乳腺癌康复者：最佳管理策略 通过调整生活方式降低风险 Risk Reduction Through Lifestyle Modifications Michelle E. Melisko, MD UCSF Helen Diller Family Comprehensive Cancer Center 通过系统管理提高依从性 Improving Adherence Through Symptom Management Debra L. Barton, PhD, AOCN, RN University of Michigan 6月6日8:00 AM - 9:15 AM 地点：S404 教育专场-改善乳腺癌的风险评估：额外的基因、额外的筛查 扩大乳腺癌患者的生殖细胞系筛查 Extending Germline Testing in Patients with Breast Cancer. Allison W. Kurian, MD, MSc Stanford University School of Medicine 风险细化和分层筛查方法 Risk Refinement and Stratify Screening Approaches Susan M. Domchek, MD - Speaker University of Pennsylvania Perelman School of Medicine 6月6日11:30 AM - 12:45 PM 地点：Hall D1 教育专场-HER-2阳性乳腺的进展和争议 HER-2阳性乳腺癌的耐药机制 Mechanisms of Resistance in HER2+ Breast Cancer Kimberly L. Blackwell, MD Duke University Medical Center HER-2阳性乳腺癌的新治疗选择 Emerging Therapeutic Options for HER2+ Breast Cancer Miguel Martin, MD, PhD Hospital General Universitario Gregorio Maraon 6月6日3:00 PM - 4:15 PM 地点：S100bc 教育专场-ASCO /北美放射学会联合会议：乳腺癌影像学 乳腺成像新技术和新方法 New Technologies and Techniques in Breast Imaging Elizabeth Ann Morris, MD - Speaker Memorial Sloan Kettering Cancer Center 6月6日4:45 PM - 6:00 PM 地点：Hall D1 教育专场：激素受体阳性乳腺癌的靶向治疗 （激素受体阳性）乳腺癌除激素治疗外，谁需要靶向药物？ Beyond Hormone Therapy for Breast Cancer: Who Needs Targeted Agents? Hope S. Rugo University of California, San Francisco 激素受体阳性乳腺癌靶向治疗的毒性管理 Managing Toxicity of Targeted Therapies for Hormone Receptor-Positive Breast Cancer DejanJuric, MD Massachusetts General Hospital Cancer Center 6月7日8:00 AM - 9:15 AM 地点：S406 教育专场-三阴性乳腺癌的改变即将来临吗？ 铂类治疗三阴性乳腺癌的最佳应用 Optimal Use of Platinum Chemotherapy in Triple-Negative Breast Cancer Rebecca Alexandra Dent, MD National Cancer Center Singapore 免疫治疗和免疫共轭物治疗三阴性乳腺癌：前景和潜力 Immunotherapy and Immunoconjugates for Triple-Negative Breast Cancer: Promise and Potential Vandana Gupta Abramson, MD Vanderbilt University Medical Center 6月7日9:45 AM - 11:00 AM 地点：S406 教育专场-激素敏感的绝经前乳腺癌的治疗 乳腺癌诊断后年轻妇女的卵巢保护和妊娠争议 Controversies in Fertility Preservation for Young Women and Pregnancy After Breast Cancer Diagnosis. Hatem A. Azim, MD, PhD Institut Jules Bordet 年轻女性激素治疗的毒性管理 Managing Hormone Therapy Toxicity in Young Women Hatem A. Azim, MD, PhD Institut Jules Bordet 6月7日11:30 AM - 12:45 PM 地点：S406 教育专场-少就是多：治疗选择的多学科讨论 局部治疗中的争议：手术和放疗 Controversies in Local Therapy: Surgery and Radiation Laura Esserman, MD, MBA University of California, San Francisco 导管原位癌的治疗争议：多少才够？ Controversies in the Treatment of Ductal Carcinoma In Situ: How Much Is Enough? Eun-Sil Shelley Hwang, MD Duke University 重点发布研究 6月5日1:40 PM - 1:55 PM 地点：Hall B1 全体大会报告 Abstract LBA1 A randomized trial (MA.17R) of extending adjuvant letrozole for 5 years after completing an initial 5 years of aromatase inhibitor therapy alone or preceded by tamoxifen in postmenopausal women with early-stage breast cancer. 6月3日4:30 PM - 6:00 PM 地点：Hall D 1 临床科学研讨会：乳腺癌治疗的未来方向：新药、新标志物 Abstract 510 MONARCH1: Results from a phase II study of abemaciclib, a CDK4 and CDK6 inhibitor, as monotherapy, in patients with HR+/HER2- breast cancer, after chemotherapy for advanced disease. 4:42 PM - 4:54 PM Abstract 511 Prognostic and predictive value of circulating ESR1 mutations in metastatic breast cancer patients (mBC) progressing under aromatase inhibitor (AI) treatment. 5:06 PM - 5:18 PM 6月4日1:15 PM - 4:15 PM 地点：HAll D2 口头报告：三阴性/细胞毒性/局部治疗 化疗 Abstract 1000 Interim joint analysis of the ABC (anthracyclines in early breast cancer) phase III trials (USOR 06-090, NSABP B-46I/USOR 07132, NSABP B-49 [NRG Oncology]) comparing docetaxel + cyclophosphamide (TC) v anthracycline/taxane-based chemotherapy regimens (TaxAC) in women with high-risk, HER2-negative breast cancer. Abstract 1001 Adjuvant capecitabine in combination with docetaxel (T), epirubicin (E), and cyclophosphamide (C) in the treatment of early breast cancer (BC): 10-year survival results from the randomized FinXX trial. Abstract 1002 PANTHER: Prospective randomized phase III trial of tailored and dose-dense versus standard tri-weekly adjuvant chemotherapy for high-risk breast cancer in the modern era of endocrine and anti-HER2 therapy. Abstract 1004 （徐兵河教授口头报告） Randomized phase III trial of utidelone, a genetically engineered epothilone analog, in combination with capecitabine versus capecitabine alone for metastatic breast cancer patients with previous taxane and anthracycline treatment. 手术治疗 Abstract 1005 A randomized controlled trial evaluating resection of the primary breast tumor in women presenting with de novo stage IV breast cancer: Turkish Study (Protocol MF07-01). Abstract 1006 A prospective analysis of surgery and survival in stage IV breast cancer (TBCRC 013). Abstract 1007 Ten-year survival results of ACOSOG Z0011: A randomized trial of axillary node dissection in women with clinical T1-2 N0 M0 breast cancer who have a positive sentinel node (Alliance). 免疫治疗 Abstract 1003 Randomized phase II/III trial of active immunotherapy with OPT-822/OPT-821 in patients with metastatic breast cancer. 6月6日1:15 PM - 4:15 PM 地点：Hall D1 口头报告（HER-2/ER） HER-2靶向治疗 Abstract 501 Evaluation of lapatinib as a component of neoadjuvant therapy for HER2+ operable breast cancer: 5-year outcomes of NSABP protocol B-41. 1:27 PM - 1:39 PM Abstract LBA503 Heritage: A phase III safety and efficacy trial of the proposed trastuzumabbiosimilar Myl-1401O versus Herceptin. 2:15 PM - 2:27 PM 内分泌治疗 Abstract 505 Predictors of recurrence during years 5-14 in 46,138 women with ER+ breast cancer allocated 5 years only of endocrine therapy (ET). Abstract LBA506 Patient-reported outcomes from MA.17R: A randomized trial of extending adjuvant letrozole for 5 years after completing an initial 5 years of aromatase inhibitor therapy alone or preceded by tamoxifen in postmenopausal women with early-stage breast cancer. Abstract 507 PALOMA-2: Primary results from a phase III trial of palbociclib (P) with letrozole (L) compared with letrozole alone in postmenopausal women with ER+/HER2- advanced breast cancer (ABC). 3:27 PM - 3:39 PM (来源：《肿瘤瞭望》编辑部） |
|
|
